CEA ELISA

Key Features and Values

– Same sample type can be used across all assays to simplify inclusion into routine serology work-up
– Ready to use reagents reduces hands-on time for assay preparation
– Long shelf life cost-effective solution by reducing wastage due to expired kits
– Suitable for inclusion on automated plate systems simplifies scale-up of test volume
– Supported by a complete panel of assays for supporting treatment monitoring of several forms of cancer

Product Description

CEA ELISA kit is a direct solid phase enzyme immunoassay for the quantitative determination of Carcinoembryonic Antigen (CEA) in human serum or plasma. CEA ELISA kit is intended for laboratory use only.

Scientific Description
Carcinoembryonic antigen (CEA) is a glycoprotein, with a molecular weight of 180 kD, involved in cell adhesion.  It is normally produced during foetal development, but the production of CEA stops before birth.  Therefore, it is not usually present in the blood of healthy adults, although levels are raised in heavy smokers.
CEA was identified in human colon cancer tissue extracts.  It was later found that serum from individuals with colorectal and other carcinomas had higher levels of CEA than healthy individuals and can be used to monitor the response to colon cancer treatment.
CEA and related genes make up the CEA family belonging to the immunoglobulin superfamily.  The most frequent cancer which causes increased CEA is cancer of the colon and rectum.  Others include cancers of the pancreas, stomach, breast, lung and certain types of thyroid and ovarian cancer.  Benign conditions which can elevate CEA include smoking, infections, inflammatory bowel disease, pancreatitis, cirrhosis of the liver and some benign tumours in the same organs in which an elevated CEA indicates cancer.  Chemotherapy and radiation therapy can cause a temporary rise in CEA due to the death of tumour cells and release of CEA into the blood stream.  Benign tumours do not usually cause an increase above 10 ng/mL.
Publications

1. Gold P, Freedman SO, J Exp Med , 121, 439(1965)
2. Zamcheck N, Adv Intern Med, 19, 413 (1974)
3. Rayncao G, Chu TM, JAMA, 220, 381 (1972)
4. Wild D, The Immunoassay Handbook., Stockton Press (1994) p444
5. Sorokin JJ, et al JAMA 228:49-53 (1974)
6. Mackay AM, et al Br. Med. Jr. 4:382-385 (1974)
7. Sikorska H, et al Cancer Detection Prev 12:321-355 (1988)
8. Minton JP, et al Cancer 42:1422-27 (1978)
9. Staab HJ, et al Am. J.Surgery 136:322-327 (1978)
10. Thomas P, et al Biochem Biophys Acta 1032:177-189 (1990)
11. Yamashita K, et al Cancer Research 47:3451-3459 (1987)
12. Hammerstrom S, et al Cancer Research 49:4852-58 (1989)
13. Ann.Inter.Med.1981;94:407-409

Download
Please enter your email address to download the DKO051-CEA-IFU.pdf
Code: DKO051
Clinical Area:
Incubation: 60+15 min
Classification: IVD, CE
Number of Tests: 96
Sample Type: Serum/Plasma
Sample Volume: 25 μL
Assay Range: 5 - 250 ng/mL